COMPLETE OVERVIEW OF INTRAAMNIOTIC INFECTION: FROM DIAGNOSIS TO TREATMENT

Intraamniotic infection (IAI), historically known as chorioamnionitis, is a significant obstetric complication characterized by inflammation of the fetal membranes, placenta, and/or amniotic fluid due to microbial invasion. This condition poses substantial risks to both the pregnant individual and the developing fetus/neonate, making its understanding, timely diagnosis, and effective management paramount in obstetric practice.

Understanding Intraamniotic Infection (IAI)

Intraamniotic infection refers to the acute inflammation of the chorion and amnion (fetal membranes), often extending to the placenta, umbilical cord, and amniotic fluid. In severe cases, it can involve the fetus itself. The American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) prefer the term IAI over chorioamnionitis, as it more accurately reflects the infectious etiology and broader involvement beyond just the chorion and amnion. While inflammation of the membranes (chorioamnionitis) can be diagnosed histologically postpartum, IAI focuses on the clinical entity during pregnancy and labor.

The primary mechanism of IAI is an ascending infection, where microorganisms from the vaginal and cervical flora ascend into the sterile amniotic cavity. Less commonly, infection can occur via hematogenous spread (e.g., Listeria monocytogenes), transabdominal contamination (e.g., during amniocentesis), or retrograde spread from the peritoneal cavity. The infectious agents are typically polymicrobial, often comprising bacteria commonly found in the lower genital tract. Common pathogens include Ureaplasma urealyticum, Mycoplasma hominis, Group B Streptococcus (GBS), Escherichia coli, various anaerobes (e.g., Bacteroides species, Peptostreptococcus species), and Gardnerella vaginalis. This microbial invasion triggers an inflammatory response in the fetal membranes and amniotic fluid, leading to the clinical signs and symptoms of IAI.

Risk Factors for Intraamniotic Infection

Several factors can increase the likelihood of developing IAI, primarily by facilitating the ascent of microorganisms into the amniotic cavity or compromising the natural defensive barriers:

• Prolonged Rupture of Membranes (PROM) or Preterm Premature Rupture of Membranes (PPROM): The loss of the physical barrier provided by intact membranes is the most significant risk factor. The longer the duration of membrane rupture, the higher the risk.
• Prolonged Labor: Extended duration of labor, particularly after PROM, provides more time for bacteria to ascend and colonize the amniotic cavity.
• Multiple Vaginal Examinations: Especially after ROM, each examination can introduce bacteria from the vaginal flora into the cervix and potentially the amniotic fluid.
• Preterm Labor: Preterm parturition itself is a strong independent risk factor, and IAI is a major cause of spontaneous preterm birth.
• Presence of Genital Tract Infections: Untreated bacterial vaginosis (BV), Group B Streptococcus (GBS) colonization, and certain sexually transmitted infections (STIs) in the lower genital tract increase the bacterial load and virulence, making ascending infection more probable.
• Internal Fetal Monitoring: The insertion of an intrauterine pressure catheter or fetal scalp electrode creates a potential pathway for bacterial entry.
• Nulliparity: First-time mothers may have longer labors, contributing to increased risk.
• Meconium-Stained Amniotic Fluid: While not a direct cause, meconium can be a sign of fetal stress, and its presence can sometimes correlate with an increased risk of infection.
• Cervical Cerclage: This procedure, performed to prevent preterm birth in certain high-risk individuals, can act as a foreign body and a potential nidus for infection.
• Immunosuppression: Conditions that compromise the maternal immune system can increase susceptibility.

Complications of Intraamniotic Infection

IAI can lead to severe adverse outcomes for both the pregnant individual and the neonate, underscoring the importance of prompt recognition and intervention:

Maternal Complications:

• Labor Dysfunction: IAI can impair uterine contractility, leading to prolonged or arrested labor and increased rates of operative delivery (instrumental vaginal delivery or Cesarean section).
• Postpartum Hemorrhage (PPH): Uterine atony (failure of the uterus to contract adequately after birth) is a common consequence, increasing the risk of significant blood loss.
• Postpartum Infections: Elevated risk of puerperal endometritis, wound infection (especially after Cesarean section), and pelvic cellulitis.
• Sepsis and Septic Shock: Progression to systemic inflammatory response syndrome (SIRS), sepsis, septic shock, and multi-organ dysfunction is possible, albeit rare, in severe, untreated cases.
• Acute Respiratory Distress Syndrome (ARDS): A severe lung condition that can be triggered by systemic inflammation.
• Disseminated Intravascular Coagulation (DIC): A life-threatening disorder of blood clotting.
• Maternal Mortality: Although rare in developed countries, severe IAI can lead to maternal death.

Fetal and Neonatal Complications:

• Preterm Birth: IAI is a leading cause of spontaneous preterm labor and delivery, contributing to the associated morbidities of prematurity.
• Neonatal Sepsis: Direct transmission of infection from the amniotic fluid to the fetus, resulting in neonatal blood stream infection, pneumonia, or meningitis. This is the most serious neonatal complication.
• Neonatal Pneumonia: Aspiration of infected amniotic fluid can lead to severe lung infection in the newborn.
• Intraventricular Hemorrhage (IVH) and Periventricular Leukomalacia (PVL): Especially in preterm infants, IAI-induced inflammation can contribute to brain injury, increasing the risk of cerebral palsy and long-term neurodevelopmental impairment.
• Bronchopulmonary Dysplasia (BPD): Chronic lung disease in neonates, particularly preterm infants, can be exacerbated or initiated by prenatal inflammation.
• Fetal Inflammatory Response Syndrome (FIRS): A systemic inflammatory response in the fetus, associated with higher risks of adverse neonatal outcomes, including multisystem organ damage and neonatal death.
• Neonatal Death: Severe IAI and its complications can unfortunately lead to fetal or neonatal demise.

Symptoms and Signs of Intraamniotic Infection

The clinical presentation of IAI can range from subtle to overt. Prompt recognition of these signs is crucial for timely intervention:

• Maternal Fever: This is the most consistent and often the earliest sign. A temperature of ≥100.4°F (38.0°C) is typically a criterion, though sustained or higher temperatures (e.g., ≥102.2°F / 39.0°C) are more indicative of definite infection. It’s important to rule out other causes of fever.
• Maternal Tachycardia: A maternal heart rate consistently above 100-120 beats per minute (bpm).
• Fetal Tachycardia: A persistent fetal heart rate greater than 160 bpm is a sensitive indicator of developing infection and fetal inflammatory response, even before maternal fever is pronounced.
• Uterine Tenderness: Pain or sensitivity upon palpation of the uterus, indicating inflammation of the uterine muscle or membranes.
• Purulent or Foul-Smelling Amniotic Fluid: If membranes are ruptured, the presence of cloudy, discolored, or malodorous fluid is a strong indicator of infection. This may be observed during vaginal examination.
• Maternal Leukocytosis: An elevated maternal white blood cell (WBC) count, typically >15,000-18,000 cells/µL, in the absence of corticosteroid administration. However, it’s important to note that labor itself can cause a physiologic rise in WBC count, making this a supportive rather than definitive sign.
• Shaking Chills: Indicative of a more significant systemic inflammatory response.

Diagnosis of Intraamniotic Infection

Diagnosis of IAI is primarily clinical, based on a combination of signs and symptoms. While laboratory tests can support the diagnosis, they are rarely definitive on their own.

• Clinical Criteria: ACOG provides guidance for diagnosis.
  • Suspected IAI: Maternal temperature ≥100.4°F (38.0°C) without another obvious source, plus the presence of one additional clinical risk factor (e.g., prolonged PROM, prolonged labor, multiple vaginal examinations) OR one additional clinical sign (e.g., fetal tachycardia, uterine tenderness, purulent vaginal discharge/amniotic fluid).
  • Confirmed IAI: Maternal temperature ≥102.2°F (39.0°C) OR maternal temperature between 100.4°F (38.0°C) and 102.2°F (39.0°C) plus one additional clinical risk factor or sign (as listed above, like fetal tachycardia, uterine tenderness, purulent fluid, elevated maternal WBC).
• Laboratory Tests (Supportive):
  • Complete Blood Count (CBC): To assess maternal leukocytosis.
  • C-Reactive Protein (CRP): Elevated levels can indicate inflammation but are non-specific.
  • Blood Cultures: Recommended if there is suspicion of maternal sepsis or bacteremia, although positive cultures are relatively uncommon in clinical IAI.
• Amniocentesis (Indications are limited): This invasive procedure is generally reserved for equivocal cases, especially in PPROM, where the benefits of definitive diagnosis might outweigh the risks.
  • Gram Stain of Amniotic Fluid: Positive for bacteria.
  • Amniotic Fluid Glucose Concentration: Low levels (<15-20 mg/dL) suggest bacterial consumption of glucose.
  • Amniotic Fluid White Blood Cell Count: Elevated.
  • Amniotic Fluid Culture: Can identify specific pathogens but results are delayed.
  • Interleukin-6 (IL-6) Levels: Elevated IL-6 in amniotic fluid is a strong marker for intraamniotic inflammation.
• Histopathological Examination of the Placenta: A definitive diagnosis of chorioamnionitis (inflammation of the membranes) can be made postpartum by examining the placenta, umbilical cord, and membranes. This is valuable for confirming the diagnosis and guiding neonatal management but is not useful for acute clinical decision-making during labor.

Treatment of Intraamniotic Infection

Once IAI is diagnosed or strongly suspected, prompt and aggressive treatment is critical to mitigate adverse outcomes.

• Antibiotics: Intravenous broad-spectrum antibiotics are the cornerstone of treatment and should be initiated immediately.
  • Standard Regimen: The most common initial regimen includes Ampicillin (or Penicillin G) combined with Gentamicin. Ampicillin covers Group B Streptococcus and some enterococci, while Gentamicin provides coverage against gram-negative bacteria, including E. coli.
  • For Cesarean Section: If a Cesarean section is performed, additional anaerobic coverage, typically with Clindamycin or Metronidazole, is often added to the regimen. This addresses the increased risk of postpartum endometritis due to anaerobic bacteria.
  • Duration: Antibiotics are generally continued until delivery. Postpartum, antibiotics are continued for a limited duration (e.g., 24-48 hours) or until the patient has been afebrile and clinically stable for a specified period, depending on clinical response and institutional guidelines.
• Antipyretics: Administration of antipyretics, such as acetaminophen, helps reduce maternal fever, which in turn can improve fetal well-being, especially by reversing fetal tachycardia caused by maternal hyperthermia.
• Delivery: IAI is an indication for delivery regardless of gestational age. The goal is to deliver the fetus and remove the infected tissue (placenta and membranes).
  • Route of Delivery: The route of delivery (vaginal vs. Cesarean section) is determined by standard obstetric indications, such as cervical dilation, fetal presentation, and maternal/fetal condition. IAI itself is not an absolute indication for Cesarean section. Vaginal delivery is often preferred if it can be achieved safely and in a timely manner. However, if there is non-reassuring fetal status or if vaginal delivery is not progressing, a Cesarean section may be indicated to expedite delivery.
  • Fetal Monitoring: Continuous fetal heart rate monitoring is essential to assess fetal response to infection and treatment, and to identify any signs of compromise.
• Neonatal Management: Neonates born to mothers with IAI are at high risk for neonatal sepsis. They should undergo a thorough evaluation for infection (including blood cultures, CBC, CRP) and often receive empiric broad-spectrum intravenous antibiotics (e.g., Ampicillin and Gentamicin) until culture results are available and sepsis is ruled out.

Prevention of Intraamniotic Infection

While not all cases of IAI are preventable, several strategies can significantly reduce its incidence and severity:

• Minimizing Vaginal Examinations: In cases of ruptured membranes, limiting the number of sterile vaginal examinations to only those essential for labor management can reduce the introduction of bacteria.
• Prompt Delivery in Term PROM: For individuals with term PROM, balancing the benefits of expectant management (allowing for spontaneous labor) with the risk of ascending infection is crucial. Often, induction of labor is initiated to expedite delivery.
• Management of Preterm Premature Rupture of Membranes (PPROM): In preterm gestations, expectant management of PPROM is often pursued to allow for fetal maturation. During this period, prophylactic broad-spectrum antibiotics (e.g., a short course of erythromycin or azithromycin plus ampicillin) are often administered to prolong the latency period and reduce the risk of chorioamnionitis and neonatal morbidity. These prophylactic regimens are distinct from the therapeutic antibiotics used for active IAI.
• Screening and Treatment of Genital Tract Infections:
  • Group B Streptococcus (GBS) Prophylaxis: Universal screening for GBS colonization between 35 and 37 weeks of gestation is recommended. Intrapartum antibiotic prophylaxis (IAP) with penicillin or ampicillin is given to GBS carriers with risk factors (e.g., PPROM, preterm labor, fever, previous GBS-affected infant) to prevent neonatal GBS disease, and may indirectly reduce IAI risk.
  • Bacterial Vaginosis (BV) and STIs: Prompt diagnosis and treatment of symptomatic BV and sexually transmitted infections during pregnancy can reduce the bacterial load in the lower genital tract, thereby decreasing the risk of ascending infection. The role of treating asymptomatic BV in preventing IAI is less clear and generally not recommended for this purpose.
• Aseptic Technique: Strict adherence to sterile technique during any invasive obstetric procedure (e.g., internal fetal monitoring, vaginal examinations, amniocentesis) is paramount.
• Patient Education: Educating pregnant individuals about the signs of infection, especially if their membranes have ruptured, empowers them to seek medical attention promptly.

In conclusion, Intraamniotic Infection is a serious obstetric complication requiring vigilance, prompt diagnosis, and aggressive management. A clear understanding of its pathophysiology, risk factors, potential complications, and effective treatment and prevention strategies is essential for all healthcare professionals involved in maternal and neonatal care to optimize outcomes for both mother and child.

References

1. American College of Obstetricians and Gynecologists (ACOG). (2017). ACOG Practice Bulletin No. 176: Intraamniotic Infection. Obstetrics & Gynecology, 129(2), e1-e12.
2. Society for Maternal-Fetal Medicine (SMFM) Publications Committee. (2016). SMFM Statement: Chorioamnionitis: Diagnosis, Treatment, and Clinical Implications. American Journal of Obstetrics & Gynecology, 215(4), B13-B16.
3. Tita, A. T. N., & Andrews, W. W. (2010). Diagnosis and management of clinical chorioamnionitis. Clinics in Perinatology, 37(2), 339-354.
4. Newton, E. R. (2009). Chorioamnionitis and intraamniotic infection. Clinical Obstetrics and Gynecology, 52(1), 17-29.
5. Goldenberg, R. L., Hauth, J. C., & DuBard, M. B. (2000). The infection-preterm labor connection. American Journal of Obstetrics & Gynecology, 183(S1), S11-S18.
6. Hagberg, H., Wennerholm, U. B., & Svedén, E. N. (2014). Inflammation in preterm birth. Seminars in Fetal & Neonatal Medicine, 19(2), 114-119.